Beeen accumulating shares for quite a while it looks like. The trial will focus on providing therapies to limited option patients. Data collected will be compared against a control segment of standard, non-treated patients. Additionally, outcomes and safety data from Arm 2 patients will be compared against Arm 1 to establish differentials in therapy modalities. $CIHN